Daniel Petrylak, MD

Expert Opinion published on August 5, 2013 in ASCO 2013 Highlights
Dr. Petrylak discusses trials in mCRPC: PSMA ADC; model for predicting OS; second-line therapy aflibercept vs placebo with dtx/predfrom the 2013 ASCO annual meeting.
Expert Opinion published on June 28, 2013 in Basic facts
Dr. Daniel Petrylak discusses the most prevalent risk factors in developing prostate cancer.
Expert Opinion published on June 28, 2013 in Treatment
Dr. Daniel Petrylak addresses prostate cancer and bone-related events.
Expert Opinion published on June 28, 2013
Dr. Daniel Petrylak discusses the use of seed implantation in prostate cancer treatment.